A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
概览
- 阶段
- 2 期
- 干预措施
- temozolomide
- 疾病 / 适应症
- Gastrinoma
- 发起方
- ECOG-ACRIN Cancer Research Group
- 入组人数
- 144
- 试验地点
- 323
- 主要终点
- Progression-free Survival
- 状态
- 进行中（未招募）
- 最后更新
- 2个月前
概览
简要总结
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.
详细描述
PRIMARY OBJECTIVES: I. To evaluate progression-free survival (PFS) associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors. SECONDARY OBJECTIVES: I. To evaluate response rates (RR) associated with temozolomide alone or temozolomide and capecitabine treatment in patients with advanced pancreatic neuroendocrine tumors. II. To evaluate overall survival (OS) associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors. III. To evaluate the toxicity associated with temozolomide alone or temozolomide and capecitabine treatment in patients with advanced pancreatic neuroendocrine tumors. IV. To evaluate the usefulness of methyl guanine methyltransferase (MGMT) status (by immunohistochemistry \[IHC\] and promoter methylation) for predicting response in pancreatic neuroendocrine tumor patients treated with either temozolomide or temozolomide and capecitabine. V. To bank radiology images for evaluation of quality, reproducibility, and compliance with computed tomography (CT) methodology. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive temozolomide orally (PO) once daily (QD) on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive capecitabine PO twice daily (BID) on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, and then every 6 months for 3 years.
研究者
入排标准
入选标准
- •Patient must have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor
- •Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained \<= 4 weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI)
- •Date of last documented disease progression must be within 12 months from date of randomization
- •Prior everolimus and/or sunitinib therapy is allowed, so long as it was discontinued \>= 4 weeks prior to randomization
- •Concurrent somatostatin analogues are allowed provided that patients
- •Have been on a stable dose for 8 weeks and
- •Have documented disease progression on that dose
- •Chemoembolization is allowed if ≥ 4 weeks from study entry. There are 2 possible scenarios:
- •If patient has hepatic disease only: they need to have progressed in the liver since chemoembolization and have measurable disease by RECIST 1.1 in order to be eligible.
- •If patient has hepatic and extrahepatic disease: they will need to have progressed inside OR outside the liver and have measureable disease by RECIST 1.1 in order to be eligible.
排除标准
- •Small cell carcinoma
- •Prior temozolomide, dacarbazine (DTIC), or capecitabine, or 5-FU (fluorouracil) therapy
- •Receiving any other investigational agents while on study treatment
- •Receiving Coumadin while on treatment; other anticoagulants are allowed
- •Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis are ineligible
- •Active or uncontrolled infection or serious medical or psychiatric illness
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine
- •Absorption issues that would limit the ability to absorb study agents
- •Patients with a history of the following within 12 months of study entry:
- •Arterial thromboembolic events
研究组 & 干预措施
Arm A (temozolomide)
Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
干预措施: temozolomide
Arm B (temozolomide and capecitabine)
Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
干预措施: temozolomide
Arm B (temozolomide and capecitabine)
Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
干预措施: capecitabine
结局指标
主要结局
Progression-free Survival
时间窗: Assessed every 3 months for 3 years and then every 6 months for years 3-5
Progression-free survival (PFS) is defined as the time from randomization to progression or death without evidence of progression. Progression was evaluated using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan-Meier method was used to estimate PFS.
次要结局
- Overall Survival(Assessed every 3 months for 3 years and then every 6 months for years 3-5)
- Proportion of Patients With Response(Assessed every 3 months for 3 years and then every 6 months for years 3-5)
- Association Between Methyl Guanine Methyltransferase (MGMT) Status by Immunohistochemistry (IHC) and Response(Assessed every 3 months for 3 years and then every 6 months for years 3-5)
- Association Between Methyl Guanine Methyltransferase (MGMT) Status by Promoter Methylation and Response(Assessed every 3 months for 3 years and then every 6 months for years 3-5)